Citigroup maintains Caris Life Sciences at Buy, raises price target to $36 from $28
Citigroup kept its Buy rating on Caris Life Sciences and increased its price target to $36 from $28, suggesting a 42.7% upside from the Nov 6 close of $25.23. Recent analyst price targets for the company range from $30 to $38.
How this was made

The 30-second read
Why it matters
Analyst target raise suggests improved growth outlook, but market reaction may be muted due to small float.
Market read
Analyst upgrade provides a modest catalyst for CRIS, primarily of interest to biotech traders.
What to watch
Potential dilution from future financing rounds.
Background
Caris Life Sciences (CRIS) is a molecular diagnostics company focused on cancer testing.
Market effects
May lift sentiment in the biotech/diagnostics sector.
Limited to US biotech investors.
Low global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoint.
Key entities
- AnalystCitigroup
Equity research firm that issued the upgraded target.

